TABLE 4.
Pharmacokinetic parameters determined for dogs given different SSG formulationsa
| Formulation | k12 (h−1 [10−3]) | k21 (h−1 [10−3]) | t1/2α (h) | t1/2β (h) | AUC0-∞ (mg · h/liter) | Vc (liters/kg) | VSS (liters/kg) | CL (liters/kg · h) | MRT0-∞ (h) |
|---|---|---|---|---|---|---|---|---|---|
| SSG | 0.69 ± 0.42 | 0.56 ± 0.22 | 0.14 ± 0.06 | 1.19 ± 0.31 | 60.7 ± 12.5 | 0.1 ± 0.0 | 0.2 ± 0.1 | 1.68 ± 0.04 | 1.37 ± 0.26 |
| SSG-dextran | 0.38 ± 0.08 | 0.67 ± 0.07 | 0.13 ± 0.06 | 0.98 ± 0.14 | 58.9 ± 8.7 | 0.1 ± 0.1 | 0.2 ± 0.1 | 1.68 ± 0.02 | 1.19 ± 0.24 |
| SSG-NIV-dextran | 0.11 ± 0.1 | 0.06 ± 0.07 | 0.52 ± 0.14 | 4.67 ± 0.88 | 67.1 ± 22.4 | 0.2 ± 0.0b | 0.3 ± 0.1b | 1.62 ± 0.07 | 2.56 ± 0.65 |
a
Dogs (n = 4/group) were given a single intravenous injection of SSG, SSG-NIV, or SSG-NIV-dextran with 10 mg of SbV/kg. k12 and k21, intercompartmental transfer rate constants; t1/2α, distribution phase half-life; t1/2β, elimination phase half-life; AUC0-∞, area under the plasma concentration-time curve projected to infinity; Vc, volume of distribution of the central compartment; VSS, steady-state volume of distribution; CL, total body clearance; MRT0-∞, mean residence time projected to infinity.
b
P < 0.05 compared to values for animals given free SSG.